-
Je něco špatně v tomto záznamu ?
Role of Human Papillomavirus in Penile Carcinomas Worldwide
L. Alemany, A. Cubilla, G. Halec, E. Kasamatsu, B. Quirós, E. Masferrer, S. Tous, B. Lloveras, G. Hernández-Suarez, R. Lonsdale, L. Tinoco, M. Alejo, I. Alvarado-Cabrero, J. Laco, N. Guimerà, E. Poblet, LE. Lombardi, C. Bergeron, O. Clavero, HR....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- DNA virů analýza MeSH
- genotyp MeSH
- infekce papilomavirem komplikace virologie MeSH
- inhibitor p16 cyklin-dependentní kinasy genetika metabolismus MeSH
- karcinom virologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidský papilomavirus 16 genetika izolace a purifikace MeSH
- lidský papilomavirus 6 genetika izolace a purifikace MeSH
- nádory penisu patologie virologie MeSH
- průřezové studie MeSH
- retrospektivní studie MeSH
- RNA virová analýza MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Afrika MeSH
- Asie MeSH
- Evropa MeSH
- Latinská Amerika MeSH
- Oceánie MeSH
- Severní Amerika MeSH
BACKGROUND: Invasive penile cancer is a rare disease with an approximately 22 000 cases per year. The incidence is higher in less developed countries, where penile cancer can account for up to 10% of cancers among men in some parts of Africa, South America, and Asia. OBJECTIVE: To describe the human papillomavirus (HPV) DNA prevalence, HPV type distribution, and detection of markers of viral activity (ie, E6*I mRNA and p16(INK4a)) in a series of invasive penile cancers and penile high-grade squamous intraepithelial lesions (HGSILs) from 25 countries. A total of 85 penile HGSILs and 1010 penile invasive cancers diagnosed from 1983 to 2011 were included. DESIGN, SETTING, AND PARTICIPANTS: After histopathologic evaluation of formalin-fixed paraffin-embedded samples, HPV DNA detection and genotyping were performed using the SPF-10/DEIA/LiPA25 system, v.1 (Laboratory Biomedical Products, Rijswijk, The Netherlands). HPV DNA-positive cases were additionally tested for oncogene E6*I mRNA and all cases for p16(INK4a) expression, a surrogate marker of oncogenic HPV activity. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HPV DNA prevalence and type distributions were estimated. RESULTS AND LIMITATIONS: HPV DNA was detected in 33.1% of penile cancers (95% confidence interval [CI], 30.2-36.1) and in 87.1% of HGSILs (95% CI, 78.0-93.4). The warty-basaloid histologic subtype showed the highest HPV DNA prevalence. Among cancers, statistically significant differences in prevalence were observed only by geographic region and not by period or by age at diagnosis. HPV16 was the most frequent HPV type detected in both HPV-positive cancers (68.7%) and HGSILs (79.6%). HPV6 was the second most common type in invasive cancers (3.7%). The p16(INK4a) upregulation and mRNA detection in addition to HPV DNA positivity were observed in 69.3% of HGSILs, and at least one of these HPV activity markers was detected in 85.3% of cases. In penile cancers, these figures were 22.0% and 27.1%, respectively. CONCLUSIONS: About a third to a fourth of penile cancers were related to HPV when considering HPV DNA detection alone or adding an HPV activity marker, respectively. The observed HPV type distribution reinforces the potential benefit of current and new HPV vaccines in the reduction of HPV-related penile neoplastic lesions. PATIENT SUMMARY: About one-third to one-quarter of penile cancers were related to human papillomavirus (HPV). The observed HPV type distribution reinforces the potential benefit of current and new HPV vaccines to prevent HPV-related penile neoplastic lesions.
Cancer Research Center University of Hawaii Honolulu HI USA
Cedars Sinai Medical Center Los Angeles CA USA
Centro de Oncología de Coimbra Coimbra Portugal
CIBER en Epidemiología y Salud Pública Barcelona Spain
DDL Diagnostic Laboratory Rijswijk The Netherlands
Eduardo Mondlane University and Maputo Central Hospital Maputo Mozambique
German Cancer Research Center Heidelberg Germany
Hospital de Oncología Centro Médico Nacional Siglo XXI IMSS Mexico D F Mexico
Hospital de Tortosa Verge de la Cinta Tarragona Spain
Hospital del Mar Barcelona Spain
Hospital General Hospitalet Barcelona Spain
Hospital General Universitario de Albacete Albacete Spain
Hospital Oncológico Quito Ecuador
Hospital San Agustín Asturias Spain
Institut Català d'Oncologia Barcelona Spain
Instituto Nacional de Cancerología Bogotá Colombia
Instituto Portugues de Oncologia de Lisboa Francisco Gentil Lisbon Portugal
Instituto Potosino de Investigación Científica y Tecnológica San Luis Potosí Mexico
Jagiellonian University Medical College Krakow Poland
Laboratoire Cerba Saint Ouen l'Aumône France
Medical School of University of Crete Crete Greece
National Cancer Center Goyang si Gyeonggi do South Korea
National Cancer Institute of Colombia Bogota Colombia
Norfolk and Norwich University Hospital NHS Foundation Trust Norfolk UK
Universidad Autónoma de Honduras Tegucigalpa Honduras
Universidad Central de Venezuela Caracas Venezuela
Universidad de Chile Santiago Chile
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017364
- 003
- CZ-PrNML
- 005
- 20180521140026.0
- 007
- ta
- 008
- 180515s2016 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2015.12.007 $2 doi
- 035 __
- $a (PubMed)26762611
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Alemany, Laia $u Institut Català d'Oncologia, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. Electronic address: lalemany@iconcologia.net.
- 245 10
- $a Role of Human Papillomavirus in Penile Carcinomas Worldwide / $c L. Alemany, A. Cubilla, G. Halec, E. Kasamatsu, B. Quirós, E. Masferrer, S. Tous, B. Lloveras, G. Hernández-Suarez, R. Lonsdale, L. Tinoco, M. Alejo, I. Alvarado-Cabrero, J. Laco, N. Guimerà, E. Poblet, LE. Lombardi, C. Bergeron, O. Clavero, HR. Shin, A. Ferrera, A. Felix, J. Germar, V. Mandys, C. Clavel, M. Tzardi, LE. Pons, V. Wain, E. Cruz, C. Molina, JD. Mota, R. Jach, J. Velasco, C. Carrilho, R. López-Revilla, MT. Goodman, WG. Quint, X. Castellsagué, I. Bravo, M. Pawlita, N. Muñoz, FX. Bosch, S. de Sanjosé, . ,
- 520 9_
- $a BACKGROUND: Invasive penile cancer is a rare disease with an approximately 22 000 cases per year. The incidence is higher in less developed countries, where penile cancer can account for up to 10% of cancers among men in some parts of Africa, South America, and Asia. OBJECTIVE: To describe the human papillomavirus (HPV) DNA prevalence, HPV type distribution, and detection of markers of viral activity (ie, E6*I mRNA and p16(INK4a)) in a series of invasive penile cancers and penile high-grade squamous intraepithelial lesions (HGSILs) from 25 countries. A total of 85 penile HGSILs and 1010 penile invasive cancers diagnosed from 1983 to 2011 were included. DESIGN, SETTING, AND PARTICIPANTS: After histopathologic evaluation of formalin-fixed paraffin-embedded samples, HPV DNA detection and genotyping were performed using the SPF-10/DEIA/LiPA25 system, v.1 (Laboratory Biomedical Products, Rijswijk, The Netherlands). HPV DNA-positive cases were additionally tested for oncogene E6*I mRNA and all cases for p16(INK4a) expression, a surrogate marker of oncogenic HPV activity. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HPV DNA prevalence and type distributions were estimated. RESULTS AND LIMITATIONS: HPV DNA was detected in 33.1% of penile cancers (95% confidence interval [CI], 30.2-36.1) and in 87.1% of HGSILs (95% CI, 78.0-93.4). The warty-basaloid histologic subtype showed the highest HPV DNA prevalence. Among cancers, statistically significant differences in prevalence were observed only by geographic region and not by period or by age at diagnosis. HPV16 was the most frequent HPV type detected in both HPV-positive cancers (68.7%) and HGSILs (79.6%). HPV6 was the second most common type in invasive cancers (3.7%). The p16(INK4a) upregulation and mRNA detection in addition to HPV DNA positivity were observed in 69.3% of HGSILs, and at least one of these HPV activity markers was detected in 85.3% of cases. In penile cancers, these figures were 22.0% and 27.1%, respectively. CONCLUSIONS: About a third to a fourth of penile cancers were related to HPV when considering HPV DNA detection alone or adding an HPV activity marker, respectively. The observed HPV type distribution reinforces the potential benefit of current and new HPV vaccines in the reduction of HPV-related penile neoplastic lesions. PATIENT SUMMARY: About one-third to one-quarter of penile cancers were related to human papillomavirus (HPV). The observed HPV type distribution reinforces the potential benefit of current and new HPV vaccines to prevent HPV-related penile neoplastic lesions.
- 650 _2
- $a Afrika $7 D000349
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a Asie $7 D001208
- 650 _2
- $a karcinom $x virologie $7 D002277
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a inhibitor p16 cyklin-dependentní kinasy $x genetika $x metabolismus $7 D019941
- 650 _2
- $a DNA virů $x analýza $7 D004279
- 650 _2
- $a Evropa $7 D005060
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a lidský papilomavirus 16 $x genetika $x izolace a purifikace $7 D052162
- 650 _2
- $a lidský papilomavirus 6 $x genetika $x izolace a purifikace $7 D052163
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Latinská Amerika $7 D007843
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a Severní Amerika $7 D009656
- 650 _2
- $a Oceánie $7 D044349
- 650 _2
- $a infekce papilomavirem $x komplikace $x virologie $7 D030361
- 650 _2
- $a nádory penisu $x patologie $x virologie $7 D010412
- 650 _2
- $a RNA virová $x analýza $7 D012367
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cubilla, Antonio $u Instituto de Investigaciones en Ciencias de la Salud-Universidad Nacional de Asunción, Asunción, Paraguay.
- 700 1_
- $a Halec, Gordana $u German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 700 1_
- $a Kasamatsu, Elena $u Instituto de Investigaciones en Ciencias de la Salud-Universidad Nacional de Asunción, Asunción, Paraguay.
- 700 1_
- $a Quirós, Beatriz $u Institut Català d'Oncologia, Barcelona, Spain.
- 700 1_
- $a Masferrer, Emili $u Hospital del Mar, Barcelona, Spain.
- 700 1_
- $a Tous, Sara $u Institut Català d'Oncologia, Barcelona, Spain.
- 700 1_
- $a Lloveras, Belén $u Hospital del Mar, Barcelona, Spain.
- 700 1_
- $a Hernández-Suarez, Gustavo $u Instituto Nacional de Cancerología, Bogotá, Colombia.
- 700 1_
- $a Lonsdale, Ray $u Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, UK.
- 700 1_
- $a Tinoco, Leopoldo $u Hospital Oncológico, Quito, Ecuador.
- 700 1_
- $a Alejo, Maria $u Hospital General Hospitalet, Barcelona, Spain.
- 700 1_
- $a Alvarado-Cabrero, Isabel $u Hospital de Oncología Centro Médico Nacional Siglo XXI, IMSS Mexico, D.F, Mexico.
- 700 1_
- $a Laco, Jan $u The Fingerland Department of Pathology, Charles University in Prague Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic.
- 700 1_
- $a Guimerà, Nuria $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
- 700 1_
- $a Poblet, Enrique $u Hospital General Universitario de Albacete, Albacete, Spain.
- 700 1_
- $a Lombardi, Luis E $u Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva-CIESAR, Hospital General San Juan de Dios, Guatemala City, Guatemala.
- 700 1_
- $a Bergeron, Christine $u Laboratoire Cerba, Saint-Ouen-l'Aumône, France.
- 700 1_
- $a Clavero, Omar $u Institut Català d'Oncologia, Barcelona, Spain.
- 700 1_
- $a Shin, Hai-Rim $u National Cancer Center, Goyang-si Gyeonggi-do, South Korea.
- 700 1_
- $a Ferrera, Annabelle $u Universidad Autónoma de Honduras, Tegucigalpa, Honduras.
- 700 1_
- $a Felix, Ana $u Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
- 700 1_
- $a Germar, Julieta $u University of Philippines, Manila, Philippines.
- 700 1_
- $a Mandys, Vaclav $u Third Faculty of Medicine, Charles University and Faculty Hospital King's Vineyards, Prague, Czech Republic.
- 700 1_
- $a Clavel, Christine $u CHU Reims, Reims, France.
- 700 1_
- $a Tzardi, Maria $u Medical School of University of Crete, Crete, Greece.
- 700 1_
- $a Pons, Luis E $u Hospital de Tortosa Verge de la Cinta, Tarragona, Spain.
- 700 1_
- $a Wain, Vincent $u Westmead Hospital, Westmead, Australia.
- 700 1_
- $a Cruz, Eugenia $u Centro de Oncología de Coimbra, Coimbra, Portugal.
- 700 1_
- $a Molina, Carla $u Universidad de Chile, Santiago, Chile.
- 700 1_
- $a Mota, Jose D $u Universidad Central de Venezuela, Caracas, Venezuela.
- 700 1_
- $a Jach, Robert $u Jagiellonian University Medical College, Krakow, Poland.
- 700 1_
- $a Velasco, Julio $u Hospital San Agustín, Asturias, Spain.
- 700 1_
- $a Carrilho, Carla $u Eduardo Mondlane University and Maputo Central Hospital, Maputo, Mozambique.
- 700 1_
- $a López-Revilla, Ruben $u Instituto Potosino de Investigación Científica y Tecnológica, San Luis Potosí, Mexico.
- 700 1_
- $a Goodman, Marc T $u Cancer Research Center, University of Hawaii, Honolulu, HI, USA; Cedars Sinai Medical Center, Los Angeles, CA, USA.
- 700 1_
- $a Quint, Wim G $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
- 700 1_
- $a Castellsagué, Xavier $u Institut Català d'Oncologia, Barcelona, Spain.
- 700 1_
- $a Bravo, Ignacio $u Institut Català d'Oncologia, Barcelona, Spain.
- 700 1_
- $a Pawlita, Michael $u German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 700 1_
- $a Muñoz, Nubia $u National Cancer Institute of Colombia, Bogota, Colombia.
- 700 1_
- $a Bosch, F Xavier $u Institut Català d'Oncologia, Barcelona, Spain.
- 700 1_
- $a de Sanjosé, Silvia $u Institut Català d'Oncologia, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
- 700 1_
- $a ,
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 69, č. 5 (2016), s. 953-61
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26762611 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521140208 $b ABA008
- 999 __
- $a ok $b bmc $g 1300988 $s 1014204
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 69 $c 5 $d 953-61 $e 20160105 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20180515
